87789-29-5 Usage
Uses
Used in Pharmaceutical Industry:
2-(Methylthio)thiazolo[4,5-d]pyrimidine-5,7-diol is used as a potential drug candidate for its antiviral and anticancer properties. Its unique molecular structure allows it to target specific biological pathways, making it a valuable asset in the development of new therapeutic agents.
Used in Medicinal Chemistry Research:
2-(Methylthio)thiazolo[4,5-d]pyrimidine-5,7-diol serves as a research tool in the study of thiazole and pyrimidine derivatives. Its potential biological activities and unique molecular structure provide valuable insights into the design and synthesis of novel compounds with therapeutic potential.
Used in Chemical Industry:
2-(Methylthio)thiazolo[4,5-d]pyrimidine-5,7-diol may have applications in the chemical industry as a building block or intermediate in the synthesis of other complex organic compounds. Its unique structure and functional groups offer opportunities for further chemical modifications and the development of new materials with diverse applications.
Check Digit Verification of cas no
The CAS Registry Mumber 87789-29-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,7,7,8 and 9 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 87789-29:
(7*8)+(6*7)+(5*7)+(4*8)+(3*9)+(2*2)+(1*9)=205
205 % 10 = 5
So 87789-29-5 is a valid CAS Registry Number.
87789-29-5Relevant academic research and scientific papers
THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
-
Page/Page column 94, (2009/05/29)
Compounds of Formulas (Ia and Ib), and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed
